Larisa J. Geskin

1.9k total citations · 1 hit paper
18 papers, 679 citations indexed

About

Larisa J. Geskin is a scholar working on Dermatology, Oncology and Molecular Biology. According to data from OpenAlex, Larisa J. Geskin has authored 18 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Dermatology, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Larisa J. Geskin's work include Cutaneous lymphoproliferative disorders research (11 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (4 papers). Larisa J. Geskin is often cited by papers focused on Cutaneous lymphoproliferative disorders research (11 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (4 papers). Larisa J. Geskin collaborates with scholars based in United States, Australia and France. Larisa J. Geskin's co-authors include H. Miles Prince, Mark Kirschbaum, Steven L. Allen, David Joske, Craig B. Reeder, Richard Piekarz, John P. Leonard, Susan E. Bates, Robin Frye and Elaine S. Jaffe and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Larisa J. Geskin

15 papers receiving 663 citations

Hit Papers

Phase II Multi-Institutional Trial of the Histone Deacety... 2009 2026 2014 2020 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
    2009 561 citations Richard Piekarz, Robin Frye et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larisa J. Geskin United States 6 432 211 199 182 167 18 679
Cecilia Kelly United States 2 651 1.5× 205 1.0× 154 0.8× 249 1.4× 159 1.0× 4 879
Elizabeth L. Lowry United States 7 152 0.4× 337 1.6× 209 1.1× 186 1.0× 342 2.0× 9 659
Alyssa Bouska United States 14 413 1.0× 33 0.2× 199 1.0× 437 2.4× 129 0.8× 30 695
Kazuaki Teshima Japan 8 327 0.8× 64 0.3× 56 0.3× 67 0.4× 126 0.8× 16 469
Nelida Sjak-Shie United States 12 367 0.8× 37 0.2× 115 0.6× 244 1.3× 88 0.5× 16 596
Anniina Virtanen Finland 10 125 0.3× 49 0.2× 66 0.3× 250 1.4× 151 0.9× 17 570
Eiji Kiyohara Japan 13 302 0.7× 62 0.3× 43 0.2× 145 0.8× 104 0.6× 40 518
Junli Yan Singapore 12 536 1.2× 14 0.1× 141 0.7× 171 0.9× 193 1.2× 22 786
Yoshiaki Chinen Japan 14 291 0.7× 20 0.1× 134 0.7× 143 0.8× 78 0.5× 49 513
Tao Ouyang China 8 260 0.6× 17 0.1× 196 1.0× 157 0.9× 64 0.4× 12 487

Countries citing papers authored by Larisa J. Geskin

Since Specialization
Citations

This map shows the geographic impact of Larisa J. Geskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larisa J. Geskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larisa J. Geskin more than expected).

Fields of papers citing papers by Larisa J. Geskin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larisa J. Geskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larisa J. Geskin. The network helps show where Larisa J. Geskin may publish in the future.

Co-authorship network of co-authors of Larisa J. Geskin

This figure shows the co-authorship network connecting the top 25 collaborators of Larisa J. Geskin. A scholar is included among the top collaborators of Larisa J. Geskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larisa J. Geskin. Larisa J. Geskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Gordon, Emily R., et al.. (2025). Skin cancer among people with intellectual disabilities: A scoping review. SHILAP Revista de lepidopterología. 7. 58–60.
2.
Porcu, Pierluigi, Youn H. Kim, Caroline Ram‐Wolff, et al.. (2025). Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial.. Journal of Clinical Oncology. 43(16_suppl). 2522–2522.
3.
4.
Brunner, Patrick M., et al.. (2024). Decoupling the association of dupilumab with cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 91(6). 1296–1298. 5 indexed citations
5.
Magro, Cynthia M., et al.. (2024). Febrile Ulceronecrotic Mucha-Habermann Disease Associated With Hemophagocytic Lymphohistiocytosis: A Case Report and Review of the Literature. American Journal of Dermatopathology. 46(4). 238–242. 1 indexed citations
6.
Gordon, Emily R., Chunhua Weng, Nicholas P. Tatonetti, et al.. (2024). Current status of artificial intelligence methods for skin cancer survival analysis: a scoping review. Frontiers in Medicine. 11. 1243659–1243659. 2 indexed citations
7.
Queen, Dawn, Christine T. Lauren, Richard D. Carvajal, et al.. (2021). Pediatric Sunscreen Coverage by Medicaid as a Primary Prevention Strategy to Reduce Melanoma Burden: A Cost-Effectiveness Analysis. 7(3). 1 indexed citations
8.
Akilov, Oleg E., Larisa J. Geskin, Takahiro Ito, et al.. (2020). TCL-127: Impact of Concomitant Steroids on Mogamulizumab Efficacy in MAVORIC. Clinical Lymphoma Myeloma & Leukemia. 20. S252–S253. 1 indexed citations
9.
Trager, Megan H., Larisa J. Geskin, & Yvonne M. Saenger. (2020). Oncolytic Viruses for the Treatment of Metastatic Melanoma. Current Treatment Options in Oncology. 21(4). 26–26. 23 indexed citations
10.
Karagounis, Theodora K., et al.. (2020). NPM1 and FLT3-TKD mutations are enriched in patients with leukemia cutis. Dermatology Online Journal. 26(7). 4 indexed citations
11.
12.
Scarisbrick, Julia, Larisa J. Geskin, M. Bagot, et al.. (2019). Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides (MF): results from the MAVORIC study. European Journal of Cancer. 119. S31–S32. 1 indexed citations
13.
Duvic, Madeleine, Larisa J. Geskin, & H. Miles Prince. (2013). Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies. Clinical Lymphoma Myeloma & Leukemia. 13(4). 377–384. 28 indexed citations
14.
Akilov, Oleg E., et al.. (2011). Vaccination with photodynamic therapy‐treated macrophages induces highly suppressive T‐regulatory cells. Photodermatology Photoimmunology & Photomedicine. 27(2). 97–107. 11 indexed citations
15.
Piekarz, Richard, Robin Frye, Maria L. Turner, et al.. (2009). Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology. 27(32). 5410–5417. 561 indexed citations breakdown →
16.
Piekarz, Richard, James R. Wright, Robin Frye, et al.. (2008). Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. Blood. 112(11). 1567–1567. 31 indexed citations
17.
Duvic, Madeleine, Debra Breneman, Theresa Pacheco, et al.. (2008). Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL). Journal of Clinical Oncology. 26(15_suppl). 14588–14588. 5 indexed citations
18.
Foss, Francine M., Madeleine Duvic, Larisa J. Geskin, et al.. (2006). Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.. Blood. 108(11). 2712–2712. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cecilia Kelly Breakdown of academic impact, for papers by Elizabeth L. Lowry Breakdown of academic impact, for papers by Alyssa Bouska Breakdown of academic impact, for papers by Kazuaki Teshima Breakdown of academic impact, for papers by Nelida Sjak-Shie Breakdown of academic impact, for papers by Anniina Virtanen Breakdown of academic impact, for papers by Eiji Kiyohara Breakdown of academic impact, for papers by Junli Yan Breakdown of academic impact, for papers by Yoshiaki Chinen Breakdown of academic impact, for papers by Tao Ouyang
Rankless by CCL
2026